This 2017 single-center, open-label phase II trial evaluated the efficacy and safety of weekly intravenous ascorbic acid (AA) in 23 chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC). The dosing regimen included 5 g in week 1, 30 g in week 2, and 60 g weekly from weeks 3 to
